Byoung Chul Cho, MD, PhD, on NSCLC: Amivantamab Plus Lazertinib for Treatment of Relapsed Disease

June 04, 2021 By The ASCO Post Staff

Byoung Chul Cho, MD, PhD, of the Yonsei Cancer Center, discusses study results that showed treatment with the EGFR-MET bispecific antibody amivantamab plus the EGFR inhibitor lazertinib yielded responses in 36% of chemotherapy-naive patients with non–small cell lung cancer whose disease progressed on osimertinib. Genetic biomarkers may be able to identify patients most likely to benefit from the combination regimen (Abstract 9006).

Related Content